To elucidate the underlying mechanisms of this reduced effectiveness for immunotherapies in lung cancer patients with EGFR mutations, we performed the current study to analyze PD-L1 protein expression status, using the FDA approved detection kit system, before and after the acquisition of resistance to EGFR-TKIs in established cell lines harboring EGFR mutations. The gene discussed is CD274; the disease is lung cancer.